{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.51","upperLimit":"2.17","value":"1.8"},{"comment":"Here, \"NA\" indicates that higher limit of 95% CI could not be evaluated due to smaller number of participants.","groupId":"OG001","lowerLimit":"0.66","upperLimit":"NA","value":"0.7"},{"groupId":"OG002","lowerLimit":"1.64","upperLimit":"4.11","value":"1.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"19"}],"units":"Participants"}],"description":"Progression-free survival is defined as the time from the date of first dose to documented disease progression, or death from any cause, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with non-NK PTCL received 12 mg dose of AZD4573 once weekly until disease progression.","id":"OG000","title":"Cohort 1 Non-NK PTCL"},{"description":"Participants with NK PTCL received 12 mg dose of AZD4573 once weekly until disease progression.","id":"OG001","title":"Cohort 2 NK PTCL"},{"description":"Participants with cHL received 12 mg dose of AZD4573 once weekly until disease progression.","id":"OG002","title":"Cohort 3 cHL"}],"paramType":"MEDIAN","populationDescription":"Full analysis set included all participants who received any amount of any study intervention.","reportingStatus":"POSTED","timeFrame":"From Screening (Day -30 to Day-1) until disease progression or survival until death (26 months).","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}